{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:16:19Z","timestamp":1777936579067,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100015364","name":"Prothena","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032703","name":"BridgeBio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Cardiol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Amyloidosis is a group of rare diseases that often manifest in multi-organ symptoms requiring an effective multidisciplinary team of care providers to manage. This study aimed to identify the best practices and key barriers to patient-centric care at US specialized amyloidosis centers (SACs) which have emerged as central hubs for multidisciplinary amyloidosis care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted and analyzed interviews with 77 stakeholders of amyloidosis diseases, including specialist physicians from 17 SACs across the US, patients, patient advocacy group representatives, and referring physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The most commonly mentioned best practices were patient-centric multidisciplinary care, timely intake of new high-risk patients, and responsiveness to patient questions. Expanding local physician education was noted as critical to earlier diagnosis. Fifteen out of 17 SACs are actively involved in clinical trials for amyloidosis treatments. Key barriers to care identified were patient distance to SACs, limited medical records and data sharing, and insurance hurdles. Most SACs keep track of metrics, such as patient volume, patient demographics, time to first appointment, as part of internal or in external registries to measure progress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings offer practical insights for optimizing amyloidosis care and highlight the structural and informational gaps that must be addressed to improve access and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795468261444669","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:39:14Z","timestamp":1777286354000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2122","authenticated-orcid":false,"given":"Jose","family":"Nativi-Nicolau","sequence":"first","affiliation":[{"name":"Mayo Clinic, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"Fajardo","sequence":"additional","affiliation":[{"name":"Duke University Hospital, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Galloway","sequence":"additional","affiliation":[{"name":"BridgeBio, CA, USA"},{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Khella","sequence":"additional","affiliation":[{"name":"University of Pennsylvania School of Medicine, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-5432","authenticated-orcid":false,"given":"Nisith","family":"Kumar","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Pfizer Inc, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Health Care, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[{"name":"Amyloidosis Research Consortium (ARC), MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Patrick","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Alnylam Pharmaceuticals, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Moffitt","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Alnylam Pharmaceuticals, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1480-7125","authenticated-orcid":false,"given":"Lori","family":"Klein","sequence":"additional","affiliation":[{"name":"Putnam Associates, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Tamariz","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Alnylam Pharmaceuticals, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Veeraraghavalu","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Prothena Biosciences Inc, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Haddad-Angulo","sequence":"additional","affiliation":[{"name":"Amyloidosis Reserach Consortium (ARC) \u2013 Amyloidosis Stakeholder Partnerships for Impact, Reach &amp; Equity (ASPIRE), MA, USA"},{"name":"Pfizer Inc, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10-31"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.12.063"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10080-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-019-1299-1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-021-00219-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795468211015230"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.6.551"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.5334\/ijic.6759"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.10.1821"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14207"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2023-323502"},{"key":"e_1_3_3_17_2","article-title":"Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: two years of experience in a neurological clinic","volume":"31","author":"Di Stefano V","year":"2024","unstructured":"Di Stefano V, Lupica A, Alonge P, et al. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: two years of experience in a neurological clinic. Eur J Neurol. 2024;31:e16065.","journal-title":"Eur J Neurol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101487"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13243634"}],"container-title":["Clinical Medicine Insights: Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795468261444669","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795468261444669","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795468261444669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:36Z","timestamp":1777692996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795468261444669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":18,"alternative-id":["10.1177\/11795468261444669"],"URL":"https:\/\/doi.org\/10.1177\/11795468261444669","relation":{},"ISSN":["1179-5468","1179-5468"],"issn-type":[{"value":"1179-5468","type":"print"},{"value":"1179-5468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"11795468261444669"}}